Immune Checkpoints, Inhibitors and Radionuclides in Prostate Cancer: Promising Combinatorial Therapy Approach

Emerging research demonstrates that co-inhibitory immune checkpoints (ICs) remain the most promising immunotherapy targets in various malignancies. Nonetheless, ICIs have offered insignificant clinical benefits in the treatment of advanced prostate cancer (PCa) especially when they are used as monot...

Descripción completa

Detalles Bibliográficos
Autores principales: Kgatle, Mankgopo M., Boshomane, Tebatso M. G., Lawal, Ismaheel O., Mokoala, Kgomotso M. G., Mokgoro, Neo P., Lourens, Nico, Kairemo, Kalevo, Zeevaart, Jan Rijn, Vorster, Mariza, Sathekge, Mike M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8071559/
https://www.ncbi.nlm.nih.gov/pubmed/33921181
http://dx.doi.org/10.3390/ijms22084109

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8071559/
https://www.ncbi.nlm.nih.gov/pubmed/33921181
http://dx.doi.org/10.3390/ijms22084109

Ejemplares similares